Insufficient scRNA-seq data for expression of CD101 at single-cell level.
Insufficient scRNA-seq data for expression of CD101 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 99% | 97.27 | 1435 / 1445 | 95% | 3.00 | 173 / 183 |
| lung | 100% | 374.55 | 577 / 578 | 89% | 2.86 | 1024 / 1155 |
| uterus | 100% | 107.28 | 170 / 170 | 87% | 2.92 | 400 / 459 |
| pancreas | 100% | 93.51 | 327 / 328 | 77% | 1.97 | 137 / 178 |
| stomach | 99% | 90.62 | 355 / 359 | 73% | 1.70 | 210 / 286 |
| intestine | 100% | 180.54 | 965 / 966 | 70% | 1.46 | 370 / 527 |
| bladder | 100% | 88.76 | 21 / 21 | 63% | 1.58 | 315 / 504 |
| breast | 79% | 54.25 | 362 / 459 | 78% | 1.84 | 873 / 1118 |
| prostate | 100% | 119.04 | 245 / 245 | 55% | 0.88 | 274 / 502 |
| ovary | 92% | 57.83 | 166 / 180 | 54% | 1.07 | 232 / 430 |
| thymus | 98% | 65.21 | 642 / 653 | 46% | 0.92 | 279 / 605 |
| skin | 81% | 86.69 | 1471 / 1809 | 59% | 1.47 | 278 / 472 |
| kidney | 75% | 35.39 | 67 / 89 | 58% | 1.24 | 527 / 901 |
| brain | 68% | 37.55 | 1792 / 2642 | 63% | 2.44 | 442 / 705 |
| adrenal gland | 100% | 122.20 | 257 / 258 | 13% | 0.28 | 29 / 230 |
| ureter | 0% | 0 | 0 / 0 | 100% | 1.39 | 1 / 1 |
| spleen | 100% | 289.29 | 240 / 241 | 0% | 0 | 0 / 0 |
| peripheral blood | 98% | 277.27 | 906 / 929 | 0% | 0 | 0 / 0 |
| liver | 73% | 26.87 | 165 / 226 | 24% | 0.49 | 98 / 406 |
| tonsil | 0% | 0 | 0 / 0 | 96% | 3.62 | 43 / 45 |
| heart | 88% | 48.16 | 757 / 861 | 0% | 0 | 0 / 0 |
| adipose | 83% | 49.04 | 1000 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 70% | 41.09 | 935 / 1335 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 48% | 1.68 | 14 / 29 |
| eye | 0% | 0 | 0 / 0 | 11% | 0.20 | 9 / 80 |
| muscle | 5% | 1.67 | 44 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0002763 | Biological process | positive regulation of myeloid leukocyte differentiation |
| GO_0007166 | Biological process | cell surface receptor signaling pathway |
| GO_0070062 | Cellular component | extracellular exosome |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0016020 | Cellular component | membrane |
| GO_0016812 | Molecular function | hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in cyclic amides |
| Gene name | CD101 |
| Protein name | Immunoglobulin superfamily member 2 (IgSF2) (Cell surface glycoprotein V7) (Glu-Trp-Ile EWI motif-containing protein 101) (EWI-101) (CD antigen CD101) CD101 molecule |
| Synonyms | V7 EWI101 IGSF2 |
| Description | FUNCTION: Plays a role as inhibitor of T-cells proliferation induced by CD3. Inhibits expression of IL2RA on activated T-cells and secretion of IL2. Inhibits tyrosine kinases that are required for IL2 production and cellular proliferation. Inhibits phospholipase C-gamma-1/PLCG1 phosphorylation and subsequent CD3-induced changes in intracellular free calcium. Prevents nuclear translocation of nuclear factor of activated T-cell to the nucleus. Plays a role in the inhibition of T-cell proliferation via IL10 secretion by cutaneous dendritic cells. May be a marker of CD4(+) CD56(+) leukemic tumor cells. . |
| Accessions | A0A1L7MZP9 ENST00000256652.8 Q93033 ENST00000682167.1 A0A1L7MZR3 ENST00000369470.1 A0A1L7MZY4 |